Search Results - "Boyle, Gary W"
-
1
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug
Published in Journal of antimicrobial chemotherapy (03-06-2024)“…The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo. A Phase 1,…”
Get full text
Journal Article -
2
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment
Published in Antimicrobial agents and chemotherapy (21-06-2022)“…As a result of a high-throughput compound screening campaign using Mycobacterium tuberculosis-infected macrophages, a new drug candidate for the treatment of…”
Get full text
Journal Article -
3
Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans
Published in Drug metabolism and disposition (01-03-2014)“…The absorption, metabolism, and excretion of darapladib, a novel inhibitor of lipoprotein-associated phospholipase A2, was investigated in healthy male…”
Get full text
Journal Article -
4
-
5
Alpibectir: Early Qualitative and Quantitative Metabolic Profiling from a First-Time-in-Human Study by Combining 19F-NMR (Nuclear Magnetic Resonance), 1H-NMR, and High-Resolution Mass Spectrometric Analyses
Published in Drug metabolism and disposition (16-07-2024)“…Alpibectir (also known as BVL-GSK098 and GSK3729098) is a new chemical entity (NCE) with a novel mechanism for the treatment of tuberculosis. The disposition…”
Get full text
Journal Article -
6
Alpibectir: Early Qualitative and Quantitative Metabolic Profiling from a First Time in Human Study by Combining 19 F-NMR, 1 H-NMR and HRMS Analyses
Published in Drug metabolism and disposition (20-05-2024)“…Alpibectir (also known as BVL-GSK098 and GSK3729098) is a new chemical entity with a novel mechanism for the treatment of tuberculosis. The disposition of…”
Get full text
Journal Article